Ovid Dividend Payout Ratio from 2010 to 2024
| OVID Stock | USD 1.05 0.02 1.94% |
Dividend Payout Ratio | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Ovid Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ovid Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 3.3 M, Selling General Administrative of 22.5 M or Total Revenue of 372.1 K, as well as many indicators such as Price To Sales Ratio of 609, Dividend Yield of 0.0 or PTB Ratio of 3.82. Ovid financial statements analysis is a perfect complement when working with Ovid Therapeutics Valuation or Volatility modules.
Ovid | Dividend Payout Ratio |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out the analysis of Ovid Therapeutics Correlation against competitors. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.